[go: up one dir, main page]

RS50660B - Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže - Google Patents

Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže

Info

Publication number
RS50660B
RS50660B RSP-2008/0550A RSP20080550A RS50660B RS 50660 B RS50660 B RS 50660B RS P20080550 A RSP20080550 A RS P20080550A RS 50660 B RS50660 B RS 50660B
Authority
RS
Serbia
Prior art keywords
dihydrotetrabenazines
pharmaceutical compositions
compositions containing
dihydrotetrabenazine
cis
Prior art date
Application number
RSP-2008/0550A
Other languages
English (en)
Inventor
Grant Johnston
Ian Clarke
Robert Turtle
Original Assignee
Biovail Laboratoires International (Barbados) Srl.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Laboratoires International (Barbados) Srl. filed Critical Biovail Laboratoires International (Barbados) Srl.
Publication of RS50660B publication Critical patent/RS50660B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

3,11 b-cis-dihidrotetrabenazin. Prijava sadrži još 28 patentnih zahteva.
RSP-2008/0550A 2004-02-11 2005-02-11 Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže RS50660B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54353104P 2004-02-11 2004-02-11
GB0403037A GB2410947B (en) 2004-02-11 2004-02-11 Pharmaceutical compounds
PCT/GB2005/000464 WO2005077946A1 (en) 2004-02-11 2005-02-11 Dihydrotetrabenazines and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
RS50660B true RS50660B (sr) 2010-06-30

Family

ID=32011732

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0550A RS50660B (sr) 2004-02-11 2005-02-11 Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže

Country Status (23)

Country Link
US (1) US20080108645A1 (sr)
EP (1) EP1716145B1 (sr)
JP (1) JP2007522193A (sr)
CN (1) CN100591680C (sr)
AT (1) ATE406370T1 (sr)
AU (1) AU2005213525B2 (sr)
CA (1) CA2555815A1 (sr)
CY (1) CY1108592T1 (sr)
DE (1) DE602005009327D1 (sr)
DK (1) DK1716145T3 (sr)
ES (1) ES2313292T3 (sr)
GB (1) GB2410947B (sr)
HK (1) HK1098138A1 (sr)
HR (1) HRP20080564T3 (sr)
MX (1) MXPA06009164A (sr)
NZ (1) NZ549105A (sr)
PL (1) PL1716145T3 (sr)
PT (1) PT1716145E (sr)
RS (1) RS50660B (sr)
RU (1) RU2365590C2 (sr)
SI (1) SI1716145T1 (sr)
WO (1) WO2005077946A1 (sr)
ZA (1) ZA200607425B (sr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843590B1 (fr) 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
RS50807B (sr) * 2005-08-06 2010-08-31 Biovail Laboratories International (Barbados) Srl. 3,11 b-cis-dihidrotetrabenazin za lečenje šizofrenije i drugih psihoza
EP2012833B1 (en) * 2006-05-02 2014-10-29 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotrabenazine derivatives and their use as imaging agents
US8039627B2 (en) * 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
WO2009055520A2 (en) * 2007-10-25 2009-04-30 General Electric Company Fluorinated dihydrotetrabenazine ether imaging agents and probes
US7897769B2 (en) 2007-10-25 2011-03-01 General Electric Company Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
US7897770B2 (en) 2007-10-25 2011-03-01 General Electric Company Fluorinated dihydrotetrabenazine ether imaging agents and probes
GB0721669D0 (en) * 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US7910738B2 (en) 2007-11-29 2011-03-22 General Electric Company Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US8013161B1 (en) 2007-12-07 2011-09-06 General Electric Company Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
US7919622B2 (en) 2007-12-07 2011-04-05 Kande Kankanamalage Dayarathna Amarasinghe Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
CN101889013B (zh) * 2007-12-07 2014-09-03 通用电气公司 作为成像剂和探针的氟烷基丁苯那嗪甲醇化合物
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
CN104744456A (zh) 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
IN2015DN01662A (sr) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2951178A4 (en) 2013-01-31 2016-07-06 Auspex Pharmaceuticals Inc VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
EP3424504A1 (en) 2013-12-03 2019-01-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP3099299A4 (en) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3102239A1 (en) 2014-02-07 2016-12-14 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
EP3102190A4 (en) 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
HUE059747T2 (hu) * 2015-03-06 2022-12-28 Auspex Pharmaceuticals Inc Eljárások rendellenes, akaratlan mozgással járó zavarok kezelésére
JP6919099B2 (ja) 2015-06-23 2021-08-18 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
CN115304596A (zh) 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
DK3394057T3 (da) * 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
US20200078352A1 (en) 2016-12-02 2020-03-12 Neurocrine Biosciences, Inc. Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
WO2018140095A2 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2022104034A (ru) 2017-04-01 2022-03-05 Адептио Фармасьютикалз Лимитед Фармацевтические композиции
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP2020512986A (ja) * 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CN107089980B (zh) * 2017-05-11 2019-08-30 合肥工业大学 一种手性苯并[a]喹嗪-2-酮类化合物及其不对称催化合成方法
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US20200230127A1 (en) * 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US12144899B2 (en) 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
JOP20200298A1 (ar) 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
WO2020037022A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2024511053A (ja) 2021-03-22 2024-03-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｖｍａｔ２阻害剤および使用方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3009918A (en) * 1961-11-21 Chz ch
US3159638A (en) * 1964-12-01 Xcha-chj
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3132147A (en) * 1964-05-05
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3123609A (en) * 1964-03-03 Benzo
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2843591A (en) * 1958-07-15 Method for preparing same
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3634431A (en) * 1969-12-22 1972-01-11 Miles Lab Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NL8601949A (nl) * 1985-07-30 1987-02-16 Glaxo Group Ltd Inrichtingen voor het toedienen van medicamenten aan patienten.
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CA2398446A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
EP2529730A1 (en) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Oral sustained-release composition
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
PT1716145E (pt) 2008-11-14
EP1716145B1 (en) 2008-08-27
AU2005213525A1 (en) 2005-08-25
CY1108592T1 (el) 2014-04-09
EP1716145A1 (en) 2006-11-02
DE602005009327D1 (de) 2008-10-09
AU2005213525B2 (en) 2011-01-06
NZ549105A (en) 2009-04-30
RU2006132329A (ru) 2008-03-20
ATE406370T1 (de) 2008-09-15
GB2410947B (en) 2008-09-17
RU2365590C2 (ru) 2009-08-27
GB0403037D0 (en) 2004-03-17
WO2005077946A1 (en) 2005-08-25
HRP20080564T3 (en) 2009-02-28
GB2410947A (en) 2005-08-17
JP2007522193A (ja) 2007-08-09
CN100591680C (zh) 2010-02-24
PL1716145T3 (pl) 2009-04-30
MXPA06009164A (es) 2007-01-26
US20080108645A1 (en) 2008-05-08
CA2555815A1 (en) 2005-08-25
SI1716145T1 (sl) 2009-02-28
CN1980924A (zh) 2007-06-13
DK1716145T3 (da) 2008-11-10
HK1098138A1 (en) 2007-07-13
ZA200607425B (en) 2008-02-27
ES2313292T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
TW200732349A (en) Anti-OX40L antibodies and methods using same
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
SE0301653D0 (sv) Novel compounds
HUS1500006I1 (hu) Benzotiazol-származék vegyületek, kompozíciók és alkalmazások
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
ATE506362T1 (de) 1-aza-bicycloä3.3.1ünonane
NO20063293L (no) Farmasoytiske forbindelser
SE0301650D0 (sv) Novel compounds
ITMI20030385A1 (it) Composizione cosmetica comprendente poliisoprene.
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
TW200621160A (en) Anti-termite agent
RS51534B (sr) Novi spoj inihbitora sinusoidne if struje i kalcijumskog inhibitora i farmaceutske smeše koje ga sadrže
BRPI0313645A2 (pt) composições de inalação com relações de droga elevadas.
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
BRPI0500536A (pt) Composição antimicrobiana
MX2007007355A (es) 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor.
ITTO20020747A1 (it) Composizione.
NL1025908A1 (nl) Farmaceutische combinatie.
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
BRPI0410638A (pt) derivados de azitromicina